Man with histologically confirmed prostate adenocarcinoma, initiating systemic therapy for metastatic disease, encompassing newly diagnosed (i.e. de novo) hormone sensitive prostate cancer (mHSPC) or first-line castration resistant prostate cancer (mCRPC)

Distant metastatic disease documented by positive bone scan or metastatic lesions on CT or MRI

Adequate health as assessed by the investigator to receive all available treatments in the trial

ECOG/WHO (Eastern Cooperative Oncology Group/ World Health Organization) performance score 0-2

Adequate organ and bone marrow function

Albumin greater than or equal to 28 g/L

Able to understand the patient information and sign written informed consent

Minimum age: 18

Other malignancies within 5 years except non-melanoma skin cancer

Within 6 months of randomization: myocardial infarction, unstable angina, angioplasty, bypass surgery, stroke, TIA (transient ischemic attack), or congestive heart failure NYHA (New York Heart Association) class III or IV

Uncontrolled hypertension

Uncontrolled hypotension

Received systemic therapy (with the exception of standard ADT) prior to study inclusion, for the CRPC indication

Any severe acute or chronic medical condition that places the patient at increased risk of serious toxicity or interferes with the interpretation of study results

Unable to comply with study procedures

Current participation in another clinical trial that will be in conflict with the present study, administration of an investigational therapeutic or invasive surgical procedure within 28 days prior to study enrolment

Patients who are unlikely to comply with the protocol

Any condition or situation which, in the opinion of the investigator, would put the subject at risk, may confound study results, or interfere with the subjects participation in this study.

Any medical condition that would make use of the study treatments contraindicated, according to the SmPC, e.g. significant heart or liver disease.